Global distribution of transfusion-transmitted virus by Prescott, L.E. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Global distribution of transfusion-transmitted virus
Citation for published version:
Prescott, LE, Simmonds, P, Pritchard, DI, Arnot, DE, Riley, EM, Greenwood, BM, Hamid, S, McClure, MO,
Lewis, JCM & Mokili, J 1998, 'Global distribution of transfusion-transmitted virus' The New England Journal
of Medicine, vol 339, no. 11, pp. 776-777. DOI: 10.1056/NEJM199809103391118
Digital Object Identifier (DOI):
10.1056/NEJM199809103391118
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
The New England Journal of Medicine
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
 CORRESPONDENCE
 
Volume 339 Number 11
 
·
 
771
 
INSTRUCTIONS FOR LETTERS TO THE EDITOR
 
Letters to the Editor are considered for publication (subject to editing and abridgment) provided they do not contain material that has been 
submitted or published elsewhere. Please note the following: •Your letter must be typewritten and triple-spaced. •Its text, not including 
references, must not exceed 400 words (please include a word count). •It must have no more than five references and one figure or table.
•It should not be signed by more than three authors. •Letters referring to a recent 
 
Journal
 
 article must be received within four weeks of its 
publication. •Please include your full address, telephone number, and fax number (if you have one). •You may send us your letter by post, fax, 
or electronic mail. 
Our address: 
 
Letters to the Editor 
 
•
 
New England Journal of Medicine
 
 
 
•
 
10 Shattuck St.
 
•
 
 Boston, MA 02115
 
Our fax numbers: 
 
617-739-9864
 
 and 
 
617-734-4457
 
Our e-mail address: 
 
letters@nejm.org
 
We cannot acknowledge receipt of your letter, but we will notify you when we have made a decision about publication. We are unable to 
provide prepublication proofs. Please enclose a stamped, self-addressed envelope if you want unpublished material returned to you.
Financial associations or other possible conflicts of interest must be disclosed. Submission of a letter constitutes permission for the Massachu-
setts Medical Society, its licensees, and its assignees to use it in the 
 
Journal’
 
s various editions (print, data base, and optical disk) and in 
anthologies, revisions, and any other form or medium.
 
Correspondence
 
Regression of Multivalvular Regurgitation 
after the Cessation of Fenfluramine 
and Phentermine Treatment
 
To the Editor:
 
 Treatment with the appetite-suppressant
drugs fenfluramine and dexfenfluramine, alone or in com-
bination with phentermine, has been associated with car-
diac-valve abnormalities.
 
1-3
 
 Five echocardiologic surveys
reviewed by the Food and Drug Administration suggested
that the prevalence of cardiac-valve abnormalities is 30 to
38 percent among patients who have taken these drugs
 
2
 
and led to the withdrawal of fenfluramine and dexfenflur-
amine from the U.S. market on September 15, 1997. Wheth-
er these lesions resolve, progress, or remain unchanged
after discontinuation of the drugs is not yet known. We re-
port the possibility of regression of multivalvular regurgi-
tation associated with fenfluramine and phentermine in a
patient who was followed for two years after she stopped
taking the drugs.
A 44-year-old woman with morbid obesity was hospi-
talized in July 1996 for atypical chest pain. Myocardial in-
farction was ruled out, and an echocardiogram revealed
normal chamber sizes and mildly reduced global systolic
function. However, moderate-to-moderately-severe aortic
regurgitation, mild mitral regurgitation, and moderate tri-
cuspid regurgitation were present. The estimated pulmo-
nary-artery pressure was mildly elevated (38 mm Hg). The
patient had no history of cardiac disease. Her only medi-
cations were 60 mg of fenfluramine and 30 mg of phen-
termine daily, which she had taken for the previous 50
weeks, during which time she had lost 40 kg (87 lb). These
drugs were discontinued, and the patient began taking
10 mg of lisinopril daily and 25 mg of metoprolol twice
daily for borderline hypertension. In December 1997, an
echocardiogram showed improved left ventricular function
and a decrease in all regurgitant lesions, with no clinically
significant change in the estimated pulmonary-artery pres-
sure. In May 1998, physical examination revealed a weight
of 198 kg (436 lb), blood pressure of 130/90 mm Hg,
and a 1–2/6 systolic ejection murmur along the left ster-
nal border. An echocardiogram obtained in June 1998 (two
years after the initial study) demonstrated only trace aortic
and tricuspid regurgitation without mitral regurgitation.
In this case, serial echocardiographic studies over a two-
year period document regression of multivalvular regurgi-
tation first discovered while the patient was taking fenflur-
amine and phentermine. Although this patient was treated
with lisinopril, the marked degree of improvement in all the
regurgitant lesions is unlikely to be attributable to this med-
ical intervention alone.
 
4
 
 Follow-up studies involving larger
numbers of affected patients are clearly needed to docu-
ment the natural history of these lesions. This case report
suggests, however, that mild-to-moderate valvular involve-
ment associated with fenfluramine and phentermine may be
at least partially reversible on discontinuation of these drugs.
L
 
AURALYN
 
 B. C
 
ANNISTRA
 
, M.D.
A
 
NTHONY
 
 J. C
 
ANNISTRA
 
, M.D.
 
Brown University School of Medicine
Providence, RI 02912
 
1.
 
Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease as-
sociated with fenfluramine–phentermine. N Engl J Med 1997;337:581-8. 
[Erratum, N Engl J Med 1997;337:1783.]
 
2.
 
Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated 
with dexfenfluramine. N Engl J Med 1997;337:636.
 
3.
 
Cardiac valvulopathy associated with exposure to fenfluramine or dexfen-
fluramine: U.S. Department of Health and Human Services interim public 
health recommendations. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
 
4.
 
Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions 
of the mitral and aortic valves. J Am Coll Cardiol 1996;28:1083-91.
 
Fetal DNA and Cells in Women 
with Systemic Sclerosis
 
To the Editor:
 
 Artlett et al. (April 23 issue)
 
1
 
 put forward
the provocative hypothesis that systemic sclerosis may be
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on July 16, 2013. For personal use only. No other uses without permission. 
 Copyright © 1998 Massachusetts Medical Society. All rights reserved. 
 772
 
·
 
September 10, 1998
 
The New England Journal  of  Medicine
caused by a graft-versus-host–like reaction induced by re-
tained fetal cells in the mother. Although the hypothesis is
intriguing, the occurrence of systemic sclerosis in men and
nulliparous women clearly indicates that antimaternal reac-
tions are not the sole basis of the disease. Furthermore, we
believe that the similarities between graft-versus-host disease
and systemic sclerosis are outweighed by considerable dif-
ferences that make the two entities readily distinguishable.
Fibrosis occurs in only a minority of patients with graft-
versus-host disease, develops late in the course of the dis-
ease, and is characterized by a central distribution, whereas
fibrosis occurs in most patients with systemic sclerosis,
develops early in the course of the disease, and is charac-
terized by an acral distribution. Liver involvement is com-
mon in graft-versus-host disease but rare in systemic sclero-
sis. Raynaud’s phenomenon is unusual in patients with
graft-versus-host disease but occurs in a majority of patients
with systemic sclerosis. Histopathologically, graft-versus-
host disease is characterized by fibrotic changes concentrat-
ed in the papillary (superficial) dermis, whereas systemic
sclerosis is characterized by a sclerotic pattern throughout
the reticular dermis, most prominently in the deep reticular
dermis at the level of subcutaneous fat. Finally, graft-ver-
sus-host disease responds to several immunosuppressive
drugs,
 
2
 
 whereas systemic sclerosis does not.
 
3
 
 Thus, the dis-
similar clinical and pathological features of graft-versus-
host disease and systemic sclerosis raise questions about
the use of graft-versus-host disease as a model for systemic
sclerosis.
M. K
 
ARI
 
 C
 
ONNOLLY
 
, M.D.
T
 
IMOTHY
 
 H. M
 
C
 
C
 
ALMONT
 
, M.D.
 
University of California, San Francisco
San Francisco, CA 94143-0517
 
1.
 
Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells 
in skin lesions from women with systemic sclerosis. N Engl J Med 1998;
338:1186-91.
 
2.
 
Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclospor-
ine and prednisone for treatment of high-risk chronic graft-
 
v
 
-host disease. 
Blood 1988;72:555-61.
 
3.
 
Pope JE. Treatment of systemic sclerosis. Rheum Dis Clin North Am 
1996;22:893-907.
 
To the Editor:
 
 Artlett et al. have clearly demonstrated the
presence of increased numbers of cells with a male chro-
mosomal pattern in skin lesions and peripheral blood from
women with a recent onset of systemic sclerosis. In their
discussion, however, the authors do not consider the pos-
sibility that the persistence of fetal cells in tissues from
women with this disease may reflect ineffective destruction
of fetal cells entering the women’s circulation during preg-
nancy due to compromised immunologic function, instead
of representing the stimulus for the development of scle-
rotic changes. An underlying immunologic abnormality
would explain not only the persistence of fetal cells in
women with systemic sclerosis but also the occurrence of
the disease in men and nulliparous women.
H
 
ARRY
 
 W. D
 
ANIELL
 
, M.D.
 
2626 Edith Ave.
Redding, CA 96001
 
The authors reply:
 
To the Editor:
 
 We agree with Drs. Connolly and McCal-
mont that the hypothesis that systemic sclerosis may be
caused by a graft-versus-host–like reaction induced by re-
tained fetal cells in the mother would not explain the patho-
genesis of systemic sclerosis in all patients. We suggested
that the passage of maternal cells across the placenta to the
fetus during pregnancy or the retention of cells from prior
blood transfusions may be an alternative mechanism for
the acquisition of foreign cells. We also agree that there are
substantial clinical and histopathological differences between
systemic sclerosis and graft-versus-host disease, but they
are similar in that tissue fibrosis and certain immunologic
abnormalities in host tissues can be induced by chimeric
cells from a graft. If fetal cells retained in the maternal cir-
culation and tissues can initiate an attack on maternal
tissues that leads to systemic sclerosis, as suggested by the
hypothesis, the resultant clinical manifestations may well
be different from those of graft-versus-host disease. Nu-
merous factors could explain such differences, including the
genetic susceptibility to systemic sclerosis, the effects of
immunosuppressive drugs given to patients receiving organ
transplants, and the possible contribution of environmen-
tal exposure to the pathogenesis of systemic sclerosis.
In response to the comments of Dr. Daniell, we believe
that there are no conclusive clinical or laboratory data to sup-
port the concept that patients with systemic sclerosis are
chronically immunosuppressed, unless they have received
treatment with glucocorticoids or other immunosuppres-
sive drugs.
C
 
AROL
 
 M. A
 
RTLETT
 
, P
 
H
 
.D.
J. B
 
RUCE
 
 S
 
MITH
 
, M.D.
S
 
ERGIO
 
 A. J
 
IMENEZ
 
, M.D.
 
Thomas Jefferson University
Philadelphia, PA 19107-5541
 
The Nephrotic Syndrome
 
To the Editor:
 
 In their review article, Orth and Ritz
(April 23 issue)
 
1
 
 state that membranous nephropathy is
the most common cause of idiopathic nephrotic syndrome
in adults, citing as a source data from a book published in
1988.
 
2
 
 According to these data, summarized in Table 1 of
the article, minimal-change nephropathy is the second most
common cause of adult nephrotic syndrome, and focal
segmental glomerulosclerosis is third, accounting for fewer
than 15 percent of such cases. However, recent data from
three separate groups
 
3-5
 
 indicate that over the past 25 years
and particularly during the past decade, there has been a
marked increase in the incidence of primary focal segmen-
tal glomerulosclerosis in adults, both overall and as a cause
of the nephrotic syndrome. In the renal-biopsy practice at
my institution, which processes over 500 native renal-
biopsy specimens a year from more than 30 hospitals in
the midwestern United States, and in the similarly busy
practice of D’Agati based in New York City, focal segmen-
tal glomerulosclerosis is now the leading cause of idio-
pathic nephrotic syndrome in adults.
 
3,5
 
 In a recent study of
the underlying causes of 233 cases of adult idiopathic
nephrotic syndrome diagnosed from 1995 to 1997,
 
5
 
 my
colleagues and I found that focal segmental glomeruloscle-
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rosis was the cause in 35 percent of cases, membranous ne-
phropathy in 33 percent, and minimal-change disease in 15
percent. Our data are similar to those of Korbet and co-
workers.
 
4
 
 Focal segmental glomerulosclerosis is particularly
common in blacks, accounting for 56 percent of cases of
idiopathic nephrotic syndrome in black adults and two
thirds of such cases in black adults under the age of 45
years. In white adults, although membranous nephropathy
remains the most common cause of idiopathic nephrotic
syndrome (frequency, 38 percent), the relative frequency
of focal segmental glomerulosclerosis as a primary nephrop-
athy has more than doubled since the late 1970s, and it is
now the second most common cause of idiopathic nephrotic
syndrome in this group, accounting for 25 percent of cases.
 
5
 
The cause of this increase in the frequency of primary focal
segmental glomerulosclerosis is not known, though it is
not related to a change in the racial composition of our
patient population, to changes in our ability as pathologists
to diagnose focal segmental glomerulosclerosis, or to chang-
es in the size or processing of renal-biopsy specimens.
 
5
 
M
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University of Chicago
Chicago, IL 60637-1470
 
1.
 
Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998;338:
1202-11.
 
2.
 
Lewis EJ. Management of the nephrotic syndrome in adults. In: Cam-
eron JS, Glasscock RJ, eds. The nephrotic syndrome. New York: Marcel 
Dekker, 1988;461-521.
 
3.
 
D’Agati V. The many masks of focal segmental glomerulosclerosis. Kid-
ney Int 1994;46:1223-41.
 
4.
 
Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial preva-
lence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996;27:
647-51.
 
5.
 
Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of 
unexplained adult nephrotic syndrome: a comparison of renal biopsy find-
ings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30:621-31.
 
To the Editor:
 
 Orth and Ritz provide a lucid and com-
prehensive review of the nephrotic syndrome. They rec-
ommend the use of ultrafiltration in particularly severe
cases. However, they do not include metolazone among
the noninvasive treatment options available as an adjunct
to loop and potassium-sparing diuretics.
The addition of metolazone to furosemide therapy can
be helpful in the treatment of refractory edema in infants
and children, leading to greater natriuresis, urinary out-
put, and weight loss than is induced by furosemide alone.
 
2
 
The use of metolazone is based on the principle of sequen-
tial nephron blockade, in which metolazone acts synergis-
tically with a loop diuretic by preventing compensatory
sodium retention in the early distal tubule. Thus, we believe
there is a place for metolazone in the management of severe
edema resistant to loop diuretics before extracorporeal
techniques are employed.
Z
 
OHAR
 
 B
 
ARZILAY
 
, M.D.
G
 
IDEON
 
 P
 
ARET
 
, M.D.
 
Chaim Sheba Medical Center
Tel-Hashomer 52621, Israel
 
1.
 
Garin EH. A comparison of combinations of diuretics in nephrotic edema. 
Am J Dis Child 1987;141:769-71.
 
2.
 
Arnold WC. Efficacy of metolazone and furosemide in children with 
furosemide-resistant edema. Pediatrics 1984;74:872-5.
 
The authors and a colleague reply:
 
To the Editor:
 
 We are aware of the report by Haas et al.
 
1
 
and similar reports
 
2-4
 
 of a trend toward an increase in the
frequency of focal segmental glomerulosclerosis in recent
decades. The report by Haas et al. was published after our
article had been completed, and we thought that without
some comment and discussion, it might have been mis-
leading to make a global statement about focal segmental
glomerulosclerosis as the number-one cause of the ne-
phrotic syndrome. Haas et al.
 
1
 
 reported that in the past two
decades the proportion of patients with focal segmental glo-
merulosclerosis and IgA glomerulonephritis among pa-
tients undergoing renal biopsy for the nephrotic syndrome
has increased. Among black adults with the nephrotic syn-
drome, 56 percent had focal segmental glomerulosclerosis,
whereas the respective value among white adults was 25
percent.
 
1
 
 The findings of Haas et al.
 
1
 
 are in agreement
with our observation that among patients who underwent
renal biopsy for the nephrotic syndrome in 1997, 30.5 per-
cent had membranous glomerulonephritis, 19.4 percent
had focal segmental glomerulosclerosis, and 11.1 percent
had minimal-change glomerulonephropathy.
Drs. Barzilay and Paret correctly point out that natriu-
resis is enhanced by sequential blockade of the nephron —
i.e., of the ascending thick loop of Henle with loop diuretics
and the distal tubule with thiazides, possibly in combination
with potassium-sparing diuretics. We could show this effect
even in patients with advanced renal failure.
 
5
 
 Metolazone,
although chemically not characterized by a thiazide ring sys-
tem, is a diuretic acting at the thiazide-sensitive distal site
and thus fits into the scheme of sequential nephron blockade
that we had proposed. We thank Drs. Barzilay and Paret,
however, since this simple method of increasing diuretic po-
tency is not widely known and is even less widely used.
S
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 R. O
 
RTH
 
, M.D.
I
 
VAN
 
 R
 
YCHLÍK
 
, M.D.
E
 
BERHARD
 
 R
 
ITZ
 
, M.D.
 
Ruperto Carola University
69115 Heidelberg, Germany
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unexplained adult nephrotic syndrome: a comparison of renal biopsy find-
ings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30:621-31.
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Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial preva-
lence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996;27:
647-51.
 
3.
 
D’Agati V. The many masks of focal segmental glomerulosclerosis. Kid-
ney Int 1994;46:1223-41.
 
4.
 
Braden G, Mulhern J, O’Shea M, Germain M, Nash S, Ucci A. Chang-
ing incidence of idiopathic glomerular diseases in adults. J Am Soc Nephrol 
1995;6:413. abstract.
 
5.
 
Fliser D, Schröter M, Neubeck M, Ritz E. Coadministration of thia-
zides increases the efficacy of loop diuretics even in patients with advanced 
renal failure. Kidney Int 1994;46:482-8.
 
HIV-Protease Inhibitors
 
To the Editor:
 
 In his review of inhibitors of human im-
munodeficiency virus (HIV)–encoded protease (April 30
issue),
 
1
 
 Dr. Flexner states that ritonavir causes hypertriglyc-
eridemia in no more than 5 percent of patients and has not
caused pancreatitis. However, we found that of 52 patients
treated with ritonavir for six months, 41 (79 percent) had
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hypertriglyceridemia (serum triglyceride concentration,
>160 mg per deciliter [1.8 mmol per liter]), with values
higher than 500 mg per deciliter (5.6 mmol per liter) in 22
patients (42 percent) and higher than 1000 mg per decili-
ter (11.3 mmol per liter) in 8 (15 percent). The risk varied
as a function of the base-line serum triglyceride concentra-
tion. Among the 24 patients who had normal base-line con-
centrations, 5 (21 percent) had concentrations higher than
500 mg per deciliter (in at least one determination at
month 1, 3, or 6), whereas 17 of the 28 patients (61 per-
cent) with high concentrations before treatment had further
increases during treatment. The risk of a serum triglyceride
concentration higher than 1000 mg per deciliter during
treatment was 4 percent in the group with normal base-line
values and 25 percent in the group with elevated base-line
values. Acute pancreatitis developed in two patients in the
latter group (serum triglyceride concentrations, 1980 and
1880 mg per deciliter [22.4 and 21.2 mmol per liter]); it
resolved with conventional medical management and the
withdrawal of ritonavir. In both patients, the serum triglyc-
eride concentration was less than 500 mg per deciliter with-
in 10 days after the withdrawal of ritonavir.
We believe that serum triglyceride concentrations should
be monitored in patients receiving ritonavir, especially those
who have elevated concentrations at base line, and that the
drug should be discontinued if the value exceeds 1000 mg
per deciliter.
G
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I
 
 P
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, M.D., D.T.M.&H., P
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.D.
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 D
 
EL
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RAVO
 
, M.D.
E
 
RCOLE
 
 C
 
ONCIA
 
, M.D.
 
University of Verona
37126 Verona, Italy
 
1.
 
Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
 
To the Editor:
 
 Flexner’s review of HIV-protease inhibi-
tors clearly explains how these drugs work and describes
the properties of the various protease inhibitors. However,
the references to the protease inhibitor saquinavir do not
explicitly differentiate between the two available formula-
tions of saquinavir: Fortovase and Invirase. Fortovase, a new,
soft-gel formulation of saquinavir, is more potent than
Invirase. Physicians treating their patients with saquinavir
should prescribe Fortovase.
In addition, two statements in the article concerning
saquinavir need to be clarified. In Table 1, the dose of sa-
quinavir is given as 600 mg three times a day. That dose is
for Invirase. The dose of Fortovase is 1200 mg three times
a day. (Fortovase, like other protease inhibitors, is recom-
mended for use in combination with two nucleoside ana-
logues.) The same table lists saquinavir’s bioavailability as less
than 4 percent, a figure that also applies only to Invirase.
The bioavailability of Fortovase is substantially higher than
that of Invirase. For physicians who want more information
about Fortovase, Hoffmann–LaRoche has a toll-free infor-
mation number (800-526-6367) staffed by health care
experts knowledgeable about all aspects of the drug’s use.
S
 
ANDRA
 
 P
 
ALLEJA
 
, M.D.
 
Hoffmann–LaRoche
Nutley, NJ 07110-1199
 
Dr. Flexner replies:
 
To the Editor:
 
 I appreciate the report by Di Perri and
colleagues about the prevalence of hypertriglyceridemia in
patients treated with ritonavir. It would be helpful to know
whether the two patients in whom pancreatitis developed
had other risk factors for it. Although the authors recom-
mend that ritonavir be discontinued in all patients with se-
rum triglyceride concentrations exceeding 1000 mg per
deciliter (11.3 mmol per liter), in some patients, hypertri-
glyceridemia may be tolerated and the benefit of continued
ritonavir therapy may outweigh the risk of pancreatitis.
I acknowledge Dr. Palleja’s comments on the difference
between the two commercially available formulations of
saquinavir. The Fortovase formulation became available
while the article was in press and therefore was not included
in the table of pharmacokinetic properties.
C
 
HARLES
 
 W. F
 
LEXNER
 
, M.D.
 
Johns Hopkins University School of Medicine
Baltimore, MD 21287-5554
 
Role of Fecal Occult-Blood Testing
 
To the Editor:
 
 Simon’s argument against population
screening for colorectal cancer by fecal occult-blood testing
(April 16 issue)
 
1
 
 contains inaccurate conclusions related to
our Minnesota screening trial.
 
2
 
 First, he concludes that the
fecal occult-blood test has limited sensitivity. An analysis
of the sensitivity of individual screening tests and of repet-
itive screening in our trial shows that of the cases detected
among subjects in compliance with the requirements of
the test, only about 10 percent were missed at the time of
the screening.
 
3
 
 Although only half the cancers diagnosed
during the trial were detected by screening, only about 50
percent of the person-years in the study were covered by
screening. The majority of interval cancers occurred in
those not in compliance (the average compliance rate was
about 75 percent) or during a four-year hiatus when no
screening was conducted. A screening test does not neces-
sarily have to be highly sensitive to be effective, as long as
its repetitive use reliably detects a neoplasm before it be-
comes incurable.
 
3
 
Second, Simon states that the specificity of fecal occult-
blood testing results in unnecessary colonoscopies and that
modification of the tests has not improved their perform-
ance. However, it is important to maximize the sensitivity
of screening tests in order to detect most potentially fatal
cancers, even if it causes false positive results. Unlike screen-
ing for some other cancers, a false positive fecal occult-
blood test is not without value. It results in a colonoscopy
— a test many now promote for primary screening; it pro-
vides reassurance about the risk of this common cancer; and
it obviates the need for further screening for up to 10 years.
Third, Simon concludes that screening by fecal occult-
blood testing is not cost effective. Although the cost of
screening everyone would be high, it must be compared
with the cost savings derived from detecting curable can-
cers and preventing cancers by resecting polyps. Using
data from the Minnesota trial, economists calculated the
cost of annual screening by fecal occult-blood testing to be
$13,581 per year of life gained (not $35,000 to $40,000,
as claimed by Dr. Simon).
 
4
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Finally, Simon criticizes screening by fecal occult-blood
testing because current compliance is low. It is not surpris-
ing that the studies he cites showed poor compliance, since
they preceded the publication of the randomized studies
showing efficacy. Now that virtually all guidelines in the
United States recommend screening, educational cam-
paigns to improve compliance are under way. Of all the
options for screening, compliance with fecal occult-blood
testing may be the easiest to achieve. In the Minnesota tri-
al, for example, compliance with both repetitive screening
and diagnostic evaluations exceeded 75 percent over a
period of 15 years.
JOHN H. BOND, M.D.
JACK S. MANDEL, PH.D.
TIMOTHY R. CHURCH, PH.D.
University of Minnesota, Minneapolis
Minneapolis, MN 55455
1. Simon JB. Should all people over the age of 50 have regular fecal occult-
blood tests? Postpone population screening until problems are solved. 
N Engl J Med 1998;338:1151-2.
2. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from co-
lorectal cancer by screening for fecal occult blood. N Engl J Med 1993;
328:1365-71. [Erratum, N Engl J Med 1993;329:672.]
3. Church TR, Ederer F, Mandel JS. Fecal occult blood screening in the 
Minnesota study: sensitivity of the screening test. J Natl Cancer Inst 1997;
89:1440-8.
4. Wagner JL, Tunis S, Brown M, Ching A, Almeida R. Cost-effectiveness 
of colorectal cancer screening in average-risk adults. In: Young GP, Rozen 
P, Levin B, eds. Prevention and early detection of colorectal cancer. Lon-
don: W.B. Saunders, 1996:321-56.
Dr. Simon replies:
To the Editor: Bond and his colleagues raise important
and valid points, but our perspectives on fecal occult-
blood screening still differ.
Sophisticated analyses of the Minnesota trial have reached
disparate conclusions about sensitivity1,2; in part, this re-
flects the conceptual distinction between the sensitivity of
the individual test and the overall sensitivity of the screening
program. Although I agree that even a relatively insensi-
tive test can be effective if used repetitively, the broad lit-
erature clearly indicates that fecal testing misses a substantial
proportion of cancers and the vast majority of neoplastic
polyps.3
Furthermore, enhanced sensitivity comes at the price of
weak specificity. In the Minnesota program, a mere 2 per-
cent of positive hydrated occult-blood tests were positive
owing to cancer (i.e., 98 percent were false positives).4
This extreme inefficiency imposes on the public an inordi-
nate number of needless invasive colonic workups and is a
huge waste of both human and economic resources. It is
true that a normal colonoscopy precipitated by a false pos-
itive test obviates further screening for up to a decade, but
surely it is much better not to have a false positive result
in the first place. Bond et al. argue that it is important to
maximize sensitivity, but I think it is equally or even more
important to maximize specificity. I hope that technical
advances will narrow the gap between us.
Cost effectiveness is a complex issue, and estimates of
cost differ. Regardless of whether true costs are at the low
or the high end of published estimates, a broad societal pro-
gram of fecal occult-blood screening would require either
a major shift of current medical resources or a major infu-
sion of new resources — most of which would be consumed
by invasive colonic evaluations based on false positive re-
sults. Whether this is justified is as much a philosophical
issue as an economic one.
Compliance in the Minnesota trial was indeed relatively
good, but this cannot be extrapolated to the general pub-
lic, because the subjects in Minnesota were all recruited
from volunteers for the American Cancer Society and oth-
er organizations.4 I acknowledged new educational cam-
paigns to improve compliance, but the outcome of such
efforts remains to be seen. The literature to date is gener-
ally pessimistic.
Bond and his colleagues have made landmark contribu-
tions, and I greatly respect their opinions. Their work and
that of others make a strong case in favor of occult-blood
screening. But there are also compelling contrary argu-
ments — arguments that have not received the attention
they deserve.
JEROME B. SIMON, M.D.
Queens University
Kingston, ON K7L 5G2, Canada
1. Church TR, Ederer F, Mandel JS. Fecal occult blood screening in the 
Minnesota study: sensitivity of the screening test. J Natl Cancer Inst 1997;
89:1440-8.
2. Pignone M, Ransohoff DF. New concepts to understand sensitivity in 
fecal occult blood testing. Gastroenterology 1997;112:A639. abstract.
3. Simon JB. Fecal occult blood testing: clinical value and limitations. 
Gastroenterologist 1998;6:66-78.
4. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from co-
lorectal cancer by screening for fecal occult blood. N Engl J Med 1993;
328:1365-71. [Erratum, N Engl J Med 1993;329:672.]
Physician-Assisted Suicide and Euthanasia 
in the United States
To the Editor: The article by Meier et al. (April 23 issue)1
on physician-assisted suicide and euthanasia in the United
States contains somewhat misleading information about
the Oregon law on assisted suicide. The authors say that
the majority of patients to whom physicians gave prescrip-
tions to assist them in suicide would have met the criteria
of the Oregon law’s regulatory safeguards for this practice.
They list such criteria as the patient’s age and prognosis,
the presence of a repeated request, the physician’s belief
that the request reflected the patient’s wishes, consultation
with another physician, and the presence of a group of
clinical symptoms such as severe discomfort, pain, depend-
ence on others, and being bedridden.
The Oregon law, unlike Dutch law, does not regard suf-
fering as a requirement for assisted suicide and refers to no
clinical symptoms. That the patient must be over 18 years
of age and have a terminal illness with a prognosis of less
than six months’ survival are statutory requirements of the
law, not safeguards. A repeated request is such a safeguard,
but only half the patients receiving prescriptions in the sur-
vey by Meier et al. met that requirement. Obtaining a second
opinion is another safeguard, but fewer than 1 percent of
physicians who assisted in suicide obtained such an opinion.
Euthanasia is prohibited by the Oregon law, so none of
the 4.7 percent of physicians who gave lethal injections were
in compliance with the law. In all cases of assisted suicide
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or euthanasia, physicians said that they “believed that the
request reflected the patient’s wishes.” This safeguard pre-
sumably refers to the stipulation in the Oregon law that
the patient’s decision be voluntary and uncoerced. The sur-
vey did not determine, however, what efforts the physician
made to find out whether this was so. Simple belief is not
enough.
Belying such belief, and perhaps most disturbing in the
survey, is the fact that, in 79 percent of cases, physicians
who gave lethal injections to patients had received no direct
request from the patients to do so. Meier has written else-
where that the likelihood that such practices would in-
crease with legalization2 and the fact that these practices
cannot be regulated have led her to cease to favor legaliza-
tion of assisted suicide or euthanasia.3
HERBERT HENDIN, M.D.
American Foundation for Suicide Prevention
New York, NY 10005
1. Meier DE, Emmons C-A, Wallenstein S, Quill T, Morrison RS, Cassel 
CK. A national survey of physician-assisted suicide and euthanasia in the 
United States. N Engl J Med 1998;338:1193-201.
2. Hendin H. Seduced by death: doctors, patients, and assisted suicide. 
New York: W.W. Norton, 1998.
3. Meier D. A change of heart on assisted suicide. New York Times. April 
24, 1998.
To the Editor: According to the survey by Meier et al.,
97 percent of those who received prescriptions for a lethal
dose of medication were men. This rate contrasts with that
of the group who received a lethal injection, of which only
57 percent were men. For lethal injection, the request was
more likely to be somewhat indirect or made by a family
member, and the doctor–patient relationship was, in some
cases, of very short duration. Although statistical probabil-
ities are not reported, the differences based on sex are likely
to be statistically significant and, at least for feminists, clin-
ically significant; they should give us pause as we debate
legalizing assisted suicide. How do the authors interpret
these findings?
SUSAN DORR GOOLD, M.D.
University of Michigan
Ann Arbor, MI 48109-0376
The authors reply:
To the Editor: Contrary to Hendin’s assertion, nowhere
in our article did we claim that Oregon’s Death with Dig-
nity Act1 requires evidence of suffering by a patient as a
safeguard. We did list (as a footnote to Table 4) that the
law requires that a patient be an adult with a terminal ill-
ness and a life expectancy of less than six months, that the
request be made by the patient, and that the request be
voluntary. Our data suggest that the majority of patients
who received a prescription for a lethal dose of medication
met these requirements. Our national survey was conducted
before the passage of the Oregon legislation; at that time,
physician-assisted suicide was illegal in all 50 states. The
fact that procedural safeguards (such as getting a second
opinion) were not followed is not surprising. Since lethal
injections are not permitted under the Oregon law, it is not
appropriate to assess the conformity of the use of lethal
injection with the legislation.
We do not know the reasons for the disparity between
men and women in the proportions of patients receiving
prescriptions for a lethal dose of medication (a weighted
97 percent were men). The survey contained data on only
36 patients who received such a prescription for whom sex
was reported. The raw (unweighted) numbers show that
two thirds (24 patients) were men. The weighted propor-
tions are considerably more lopsided because the seven pre-
scriptions written by general internists or family practition-
ers (groups of physicians whose responses were weighted
more heavily to reflect their preponderance in the popula-
tion of U.S. physicians) were all written for men. Given the
low prevalence of such prescriptions in our study, it is un-
certain whether the sex differences found were in fact true
differences or whether they were an artifact of the statisti-
cal weighting necessary to analyze the survey. The raw data
suggest that both assistance with suicide from a physician
and euthanasia are more commonly requested and re-
ceived by men, with men making up 60 to 66 percent of
the patients described. Most,2-4 but not all,5 previous sur-
veys have found a similar sex distribution. Possible expla-
nations for this disparity are that women are less inclined
to seek to hasten their own deaths, that they are uncom-
fortable asking their physicians (most of whom are men)
for help, or some other factor or combination of factors.
DIANE E. MEIER, M.D.
R. SEAN MORRISON, M.D.
SYLVAN WALLENSTEIN, PH.D.
Mount Sinai School of Medicine
New York, NY 10029
1. Oregon Death with Dignity Act, Or. Laws ch. 3 (initiative measure 
no. 16), 1995.
2. Back AL, Wallace JI, Starks HE, Pearlman RA. Physician-assisted suicide 
and euthanasia in Washington state: patient requests and physician respons-
es. JAMA 1996;275:919-25.
3. Pijnenborg L, van der Maas PJ, van Delden JJM, Looman CWN. Life-
terminating acts without explicit request of patient. Lancet 1993;341:
1196-9.
4. van der Wal G, van der Maas PJ, Bosma JM, et al. Evaluation of the 
notification procedure for physician-assisted death in the Netherlands. 
N Engl J Med 1996;335:1706-11.
5. van der Maas PJ, van der Wal G, Haverkate I, et al. Euthanasia, physician-
assisted suicide, and other medical practices involving the end of life in the 
Netherlands, 1990–1995. N Engl J Med 1996;335:1699-705.
Global Distribution
of Transfusion-Transmitted Virus
To the Editor: Transfusion-transmitted virus has recently
been identified as a potential cause of post-transfusion non-
A, non-B, non-C hepatitis.1 The virus has a single-stranded
DNA genome whose organization is similar to those of
members of the Parvoviridae.2 Transient viremia due to
transfusion-transmitted virus was detected by the polymer-
ase chain reaction (PCR) in three patients six to eight weeks
after the transfusion of blood components and coincided
with modest elevations of alanine aminotransferase. It has
been proposed that transfusion-transmitted virus is the chlo-
roform-resistant non-A, non-B agent shown to cause tran-
sient alanine aminotransferase elevations in chimpanzees.3
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To understand more about the distribution of transfusion-
transmitted virus infection, we investigated the prevalence
of infection in a wide range of geographically separated
human populations and among chimpanzees in Africa.
Blood samples were obtained from people inhabiting equa-
torial forests in Ecuador, northern Brazil, and Papua New
Guinea (Karkar Island) and from people living in predom-
inantly rural, farming communities in Gedaref in eastern
Sudan, the Lower River Division in the Gambia, around La-
gos in Nigeria, and the Kinshasa region in the Democratic
Republic of the Congo. Samples were obtained from blood
donors in Karachi, Pakistan, and from wild animals in an
area extending from Central Africa to West Africa. The sam-
ples had originally been collected for studies of other viruses
and parasites.
Sequences of transfusion-transmitted virus were amplified
by heminested PCR according to previously described
conditions.2 Full precautions were taken to prevent contam-
ination of the PCR, with primary and secondary reactions
performed in separate laboratories and negative controls
included with each set of samples.
We found high frequencies of viremia due to transfu-
sion-transmitted virus in most of the study populations,
with values ranging from 16 percent in Pakistan to 83 per-
cent in the Gambia (Table 1). Transfusion-transmitted
virus DNA sequences were also detected in one of the
chimpanzees. Although Nishizawa et al. reported that in-
fection with transfusion-transmitted virus was transient
among blood recipients,1 the high frequencies of viremia
that we found indicate that the infection can also be per-
sistent. The mechanism by which infection can be main-
tained at such high frequencies and the routes of transmis-
sion are unclear. It is also difficult to assess the clinical
significance of the infection and whether it causes disease
without detailed clinical assessment or prospective longitu-
dinal studies. However, the finding of transfusion-trans-
mitted virus infection in such a large proportion of the
study groups highlights the need for further investigations.
LINDA E. PRESCOTT, PH.D.
PETER SIMMONDS, M.R.C.PATH.
University of Edinburgh
Edinburgh, EH8 9AG, United Kingdom
AND INTERNATIONAL COLLABORATORS
(The international collaborators were Professor D.I. Pritchard,
University of Nottingham, Nottingham, United Kingdom; Dr.
D.E. Arnot and Dr. E.M. Riley, University of Edinburgh, Edin-
burgh, United Kingdom; Dr. B.M. Greenwood, Medical Research
Council Laboratories, Fajara, the Gambia; Dr. S. Hamid, Aga
Khan University, Karachi, Pakistan; Dr. M.O. McClure, St. Mary’s
Hospital, London; Dr. J.C.M. Lewis, International Zoo Veterinary
Group, Keighley, United Kingdom, and Dr. J. Mokili, University
of Edinburgh, Edinburgh, United Kingdom.)
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Reforming Medicare: The Gramm Plan
To the Editor: Under the plan proposed by Gramm et al.
(April 30 issue),1 uninsured workers would pay for current
Medicare recipients and their own future benefits, but
they still would have no current medical insurance. Why
not have an investment-based Medicare system for all
(“Americare”), so those who pay for the health care of
others will be covered as well? As the most prosperous so-
ciety in the world, we have the resources to provide uni-
versal health care. Do we have the wisdom and the will?
GERALD FRANKEL, M.D.
1441 Redbud Blvd.
McKinney, TX 75069
1. Gramm P, Rettenmaier AJ, Saving TR. Medicare policy for future gen-
erations — a search for a permanent solution. N Engl J Med 1998;338:
1307-10.
To the Editor: Senator Gramm’s proposed health care
policy is flawed because it is based on three false assump-
tions. The first false assumption, shared by many, is that the
goal is to save Medicare. Medicare began as a stopgap
*Data on subjects from Scotland and Japan have been reported previ-
ously.2,4
†The samples were mixed in pools of five and tested by PCR. To allow
for the possibility that some pools might contain more than one positive
sample, the prevalence was calculated from the adjusted frequency f, accord-
ing to the following Poisson relation: f=¡ln(f0), where f0 is the frequency
of negative pools.
TABLE 1. VIREMIA DUE TO FREQUENCY OF TRANSFUSION-
TRANSMITTED VIRUS ON PCR TESTING IN VARIOUS GROUPS.
COUNTRY* SUBJECTS VIREMIA 
NO. POSITIVE/
TOTAL NO.
TESTED
PREVALENCE
(%)
Scotland Blood donors 19/1000 1.9
Japan Blood donors 34/290 12
Pakistan Blood donors 25/45 pools of 5 16†
Sudan Rural people 5/70 7
Nigeria Rural, periurban 
people
32/63 51
The Gambia Rural people 63/76 83
Congo Rural people 32/72 44
Papua New 
Guinea
Indigenous rural 
people
51/69 74
Ecuador Indigenous rural 
people
57/96 59
Brazil Indigenous rural 
people
18/91 20
Central and West 
Africa
Chimpanzees 1/31 3
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political compromise and has become a patient–provider
obstacle course that encourages profit taking with one
hand and ratchets down revenues with the other. The pol-
icy makers’ goal should not be to save such a system.
Rather, the goal should be to preserve health care benefits
for people now turning 65 whose contributions to Medi-
care have already been spent in the current transfer-pay-
ment financing model. The best way to do that is not sim-
ply to tinker with a system begging to be fundamentally
changed.
The second false assumption is that health care policy is
a unidimensional issue. There is much more to reforming
health care than just finding a financing mechanism agree-
able to a variety of interests. For example, it is time to “fol-
low the money” spent on health care. If one runs water
through one end of a hose at a steady high pressure and
only a trickle of water comes out the other end of the hose,
one knows to look for a hole in the hose. There is such a
leak in Medicare. The current system is characterized as
much by expenditures on financial, legal, and political ma-
neuvering as by spending what it takes to provide depend-
able, affordable health care services to an aging population.
The third false assumption is that health care is the right
only of Medicare beneficiaries and insurance beneficiaries.
In every other major nation in the world, health care is
considered a customary right of citizenship, however
flawed the systems by which those countries try to fulfill
that principle. The common mistake is to believe that this
is because other countries have more of a social conscience
than we do in the United States. But the economic reality
is that those countries appreciate what we have apparently
not yet discovered — that is, like it or not, failing to meet
the needs of entire populations results in increased health
care costs for the entitled few.
RICHARD E. THOMPSON, M.D.
1975 Orange Ct.
Palm Harbor, FL 34683
The authors reply:
To the Editor: Providing health care for the aged involves
real resources, and because we have elected to finance the
purchase of these resources by transferring income from
the working generation to the retired generation, we are
at the mercy of demographics. The tax rates that will be
required to allow the baby boomers to consume health
care at the current per capita rate will result in payroll taxes
that may well exceed 35 percent and a total tax burden on
the younger generation in excess of 60 percent. If the
younger generation is unwilling to give up that much to
help their elders, any promises we have made to the baby
boomers will remain just that — promises.
To gain control over this problem, we must accomplish
two things. First, we must slow the continued increase in
per capita health care expenditures; second, we must in-
troduce a financing system that allows each generation to
pay for its own retirement health care. These two parts of
the problem are separable, and although converting Medi-
care to an investment-based system can hardly be called
tinkering, no one would argue that rising health care costs
are unimportant or that the existing system is not without
its inefficiencies.
However, a reform effort with only a traditional focus
on per capita costs is doomed to failure if Medicare’s basic
financial structure is not put on a sound footing. The gen-
erational transfer system now used reduces the nation’s
wealth and income. By moving to a system in which each
generation prepays its retirement health care insurance, we
will set in motion rising national wealth that will ultimate-
ly produce the additional national income that provides
the doctors, nurses, pharmaceuticals, hospital beds, and
other medical equipment that will be required by the
baby-boom generation.
As for the currently uninsured, investment is the ideal
method of preparing to pay for a large known future ex-
pense such as health care during retirement, but you do not
earn compound interest when the principal is spent on the
current consumption of health care. These are two separate
problems and should be treated as such. The most impor-
tant thing we can do to help the uninsured is to provide
persons seeking to buy individual health insurance with the
same tax break General Motors gets when it buys health in-
surance for its employees. This would reduce the cost of
health insurance for such persons by as much as a third.
PHIL GRAMM
U.S. Senate
Washington, DC 20510
ANDREW J. RETTENMAIER, PH.D.
THOMAS R. SAVING, PH.D.
Texas A&M University
College Station, TX 77843
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